| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 113 | 2025 | 817 | 24.560 |
Why?
|
| Autoantibodies | 42 | 2025 | 433 | 7.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 27 | 2024 | 1272 | 6.670 |
Why?
|
| C-Peptide | 25 | 2025 | 113 | 4.860 |
Why?
|
| Islets of Langerhans | 19 | 2024 | 174 | 4.630 |
Why?
|
| Insulin Resistance | 9 | 2024 | 642 | 3.210 |
Why?
|
| Insulin | 28 | 2025 | 1203 | 2.780 |
Why?
|
| Diabetic Ketoacidosis | 12 | 2024 | 160 | 2.410 |
Why?
|
| Blood Glucose | 21 | 2025 | 1134 | 2.310 |
Why?
|
| Autoimmunity | 13 | 2020 | 172 | 2.000 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2025 | 2656 | 1.990 |
Why?
|
| Adolescent | 71 | 2025 | 19423 | 1.980 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 6 | 2022 | 24 | 1.850 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2025 | 3176 | 1.820 |
Why?
|
| Hypoglycemic Agents | 12 | 2024 | 443 | 1.790 |
Why?
|
| Child | 75 | 2025 | 24606 | 1.740 |
Why?
|
| HLA-DQ Antigens | 7 | 2024 | 21 | 1.730 |
Why?
|
| Insulin-Secreting Cells | 7 | 2024 | 148 | 1.520 |
Why?
|
| Glucose Tolerance Test | 11 | 2025 | 208 | 1.440 |
Why?
|
| Humans | 137 | 2025 | 125358 | 1.390 |
Why?
|
| Diabetes Complications | 2 | 2023 | 203 | 1.300 |
Why?
|
| Child, Preschool | 43 | 2025 | 14145 | 1.240 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 127 | 1.130 |
Why?
|
| Glutamate Decarboxylase | 6 | 2017 | 37 | 1.120 |
Why?
|
| Disease Progression | 20 | 2025 | 2084 | 1.100 |
Why?
|
| Male | 77 | 2025 | 61561 | 1.090 |
Why?
|
| Female | 78 | 2025 | 66815 | 1.070 |
Why?
|
| Young Adult | 25 | 2025 | 9058 | 0.970 |
Why?
|
| HLA-DR3 Antigen | 1 | 2024 | 1 | 0.950 |
Why?
|
| HLA-DR4 Antigen | 1 | 2024 | 6 | 0.940 |
Why?
|
| Hypoglycemia | 6 | 2018 | 192 | 0.910 |
Why?
|
| Body Mass Index | 10 | 2023 | 1563 | 0.910 |
Why?
|
| Immunoglobulin A | 2 | 2024 | 207 | 0.850 |
Why?
|
| Adult | 39 | 2025 | 29540 | 0.840 |
Why?
|
| Leptin | 2 | 2023 | 213 | 0.820 |
Why?
|
| Puberty | 2 | 2021 | 95 | 0.810 |
Why?
|
| Risk Factors | 23 | 2025 | 10296 | 0.810 |
Why?
|
| Minority Groups | 3 | 2020 | 243 | 0.780 |
Why?
|
| Biomarkers | 9 | 2024 | 3106 | 0.760 |
Why?
|
| Obesity | 10 | 2022 | 2252 | 0.760 |
Why?
|
| Infant | 24 | 2024 | 12601 | 0.750 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 383 | 0.740 |
Why?
|
| Metformin | 1 | 2023 | 150 | 0.740 |
Why?
|
| Genetic Linkage | 2 | 2021 | 455 | 0.720 |
Why?
|
| Hyperglycemia | 4 | 2020 | 227 | 0.710 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 108 | 0.690 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 300 | 0.670 |
Why?
|
| Diagnostic Errors | 1 | 2024 | 334 | 0.670 |
Why?
|
| Cohort Studies | 17 | 2025 | 4828 | 0.610 |
Why?
|
| Overweight | 7 | 2020 | 363 | 0.600 |
Why?
|
| Flatfishes | 3 | 2006 | 3 | 0.580 |
Why?
|
| Age of Onset | 6 | 2020 | 601 | 0.580 |
Why?
|
| Fish Diseases | 3 | 2006 | 10 | 0.580 |
Why?
|
| Phenotype | 9 | 2024 | 4270 | 0.570 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 290 | 0.570 |
Why?
|
| Prospective Studies | 15 | 2024 | 6142 | 0.560 |
Why?
|
| Adiposity | 2 | 2020 | 190 | 0.560 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 876 | 0.550 |
Why?
|
| Precision Medicine | 4 | 2024 | 321 | 0.550 |
Why?
|
| Osteocalcin | 1 | 2017 | 42 | 0.530 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3407 | 0.530 |
Why?
|
| Prognosis | 8 | 2024 | 4686 | 0.530 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2025 | 11 | 0.530 |
Why?
|
| Protozoan Infections, Animal | 2 | 2006 | 3 | 0.520 |
Why?
|
| Prediabetic State | 3 | 2015 | 58 | 0.510 |
Why?
|
| Age Factors | 10 | 2024 | 2818 | 0.510 |
Why?
|
| Twins, Monozygotic | 3 | 2008 | 117 | 0.500 |
Why?
|
| Hospitalization | 1 | 2024 | 1791 | 0.500 |
Why?
|
| Diseases in Twins | 2 | 2008 | 94 | 0.470 |
Why?
|
| Thinness | 1 | 2014 | 71 | 0.440 |
Why?
|
| Insulin Infusion Systems | 4 | 2023 | 65 | 0.430 |
Why?
|
| Glucose | 5 | 2023 | 878 | 0.410 |
Why?
|
| Middle Aged | 20 | 2025 | 26765 | 0.400 |
Why?
|
| Haplotypes | 7 | 2024 | 521 | 0.390 |
Why?
|
| Health Personnel | 1 | 2017 | 510 | 0.390 |
Why?
|
| Family | 4 | 2025 | 561 | 0.380 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 675 | 0.370 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2023 | 122 | 0.370 |
Why?
|
| Sex Factors | 6 | 2024 | 1275 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2025 | 16363 | 0.360 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 5171 | 0.350 |
Why?
|
| Socioeconomic Factors | 5 | 2018 | 860 | 0.340 |
Why?
|
| Patient Preference | 1 | 2011 | 118 | 0.340 |
Why?
|
| Eukaryota | 2 | 2006 | 23 | 0.320 |
Why?
|
| Prevalence | 6 | 2024 | 2467 | 0.320 |
Why?
|
| Antibody Specificity | 3 | 2018 | 204 | 0.310 |
Why?
|
| Social Class | 3 | 2020 | 190 | 0.300 |
Why?
|
| Zinc Transporter 8 | 3 | 2017 | 6 | 0.290 |
Why?
|
| HLA Antigens | 3 | 2025 | 238 | 0.290 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 605 | 0.280 |
Why?
|
| Twins, Dizygotic | 2 | 2004 | 42 | 0.270 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2006 | 41 | 0.250 |
Why?
|
| Major Histocompatibility Complex | 4 | 2017 | 51 | 0.250 |
Why?
|
| Dyslipidemias | 2 | 2021 | 235 | 0.250 |
Why?
|
| Health Status Disparities | 2 | 2020 | 229 | 0.250 |
Why?
|
| Cluster Analysis | 2 | 2024 | 404 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1961 | 0.240 |
Why?
|
| Social Determinants of Health | 2 | 2023 | 125 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2024 | 678 | 0.220 |
Why?
|
| Cytokines | 3 | 2024 | 1291 | 0.220 |
Why?
|
| Alleles | 5 | 2017 | 1618 | 0.220 |
Why?
|
| Weight Gain | 3 | 2017 | 400 | 0.220 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 63 | 0.220 |
Why?
|
| Siblings | 1 | 2004 | 186 | 0.210 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2022 | 70 | 0.210 |
Why?
|
| Immunity, Innate | 1 | 2006 | 372 | 0.210 |
Why?
|
| HLA-DRB1 Chains | 3 | 2017 | 38 | 0.210 |
Why?
|
| Genetic Vectors | 2 | 2017 | 940 | 0.210 |
Why?
|
| Fabaceae | 1 | 2023 | 24 | 0.210 |
Why?
|
| Genotype | 5 | 2018 | 2570 | 0.190 |
Why?
|
| Immune System | 2 | 2020 | 90 | 0.190 |
Why?
|
| Acanthosis Nigricans | 1 | 2022 | 10 | 0.190 |
Why?
|
| Self-Management | 2 | 2020 | 95 | 0.190 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 77 | 0.190 |
Why?
|
| Celiac Disease | 2 | 2017 | 67 | 0.190 |
Why?
|
| United States | 9 | 2020 | 10908 | 0.190 |
Why?
|
| Longitudinal Studies | 5 | 2025 | 1320 | 0.180 |
Why?
|
| Genetic Association Studies | 1 | 2025 | 779 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 314 | 0.180 |
Why?
|
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2005 | 140 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 509 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2021 | 184 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2016 | 439 | 0.170 |
Why?
|
| HLA-DR2 Antigen | 1 | 1999 | 6 | 0.170 |
Why?
|
| Antibodies, Heterophile | 1 | 1999 | 10 | 0.170 |
Why?
|
| HLA-DQ alpha-Chains | 4 | 2017 | 17 | 0.170 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 33 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 24 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2020 | 122 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 252 | 0.160 |
Why?
|
| Spain | 5 | 2007 | 60 | 0.160 |
Why?
|
| Global Health | 1 | 2024 | 570 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2015 | 36 | 0.160 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 1086 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 54 | 0.160 |
Why?
|
| Cation Transport Proteins | 2 | 2017 | 94 | 0.150 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mass Screening | 2 | 2022 | 785 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 171 | 0.150 |
Why?
|
| Registries | 4 | 2022 | 1434 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2024 | 724 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2025 | 318 | 0.140 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 282 | 0.140 |
Why?
|
| Seasons | 3 | 2006 | 312 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2182 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 260 | 0.140 |
Why?
|
| Leg | 1 | 1997 | 155 | 0.130 |
Why?
|
| Gene Frequency | 1 | 2018 | 729 | 0.130 |
Why?
|
| Pandemics | 1 | 2024 | 1113 | 0.130 |
Why?
|
| Communication | 2 | 2019 | 511 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 61 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2017 | 1016 | 0.130 |
Why?
|
| Cultural Characteristics | 1 | 2016 | 41 | 0.130 |
Why?
|
| Retroviridae | 1 | 2016 | 196 | 0.130 |
Why?
|
| Exercise | 1 | 2022 | 814 | 0.130 |
Why?
|
| Glucagon | 1 | 2016 | 184 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2001 | 144 | 0.120 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.120 |
Why?
|
| Perception | 1 | 2017 | 220 | 0.120 |
Why?
|
| Time Factors | 5 | 2016 | 6311 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 62 | 0.120 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 75 | 0.120 |
Why?
|
| Roma | 1 | 1995 | 4 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 1995 | 5 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 77 | 0.120 |
Why?
|
| Child Development | 1 | 2017 | 269 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 1997 | 163 | 0.120 |
Why?
|
| Cloning, Molecular | 1 | 2016 | 898 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 235 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2016 | 358 | 0.110 |
Why?
|
| Language | 1 | 2016 | 196 | 0.110 |
Why?
|
| Epitopes | 1 | 2016 | 433 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 142 | 0.110 |
Why?
|
| Qualitative Research | 1 | 2017 | 540 | 0.110 |
Why?
|
| Adipokines | 1 | 2014 | 60 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 480 | 0.110 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 819 | 0.110 |
Why?
|
| Nuclear Family | 1 | 2013 | 49 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1445 | 0.100 |
Why?
|
| Lignans | 1 | 2012 | 3 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2020 | 8273 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 421 | 0.100 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 57 | 0.100 |
Why?
|
| Flavonoids | 1 | 2012 | 77 | 0.100 |
Why?
|
| Insulin Antibodies | 3 | 2017 | 7 | 0.100 |
Why?
|
| Pancreas, Artificial | 1 | 2011 | 2 | 0.090 |
Why?
|
| Self Administration | 1 | 2011 | 42 | 0.090 |
Why?
|
| Twin Studies as Topic | 2 | 2001 | 15 | 0.090 |
Why?
|
| Stem Cells | 1 | 2016 | 709 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 1909 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 344 | 0.090 |
Why?
|
| Random Allocation | 2 | 2016 | 439 | 0.090 |
Why?
|
| Oxazolidinones | 2 | 2001 | 33 | 0.090 |
Why?
|
| Pedigree | 3 | 2021 | 1610 | 0.090 |
Why?
|
| Aging | 1 | 2017 | 1182 | 0.090 |
Why?
|
| Diet | 2 | 2012 | 1138 | 0.090 |
Why?
|
| Pregnancy | 1 | 2022 | 7226 | 0.080 |
Why?
|
| Animals | 10 | 2017 | 34318 | 0.080 |
Why?
|
| Aquaculture | 2 | 2006 | 6 | 0.080 |
Why?
|
| HLA-DQ beta-Chains | 2 | 2017 | 15 | 0.080 |
Why?
|
| Risk | 3 | 2017 | 759 | 0.080 |
Why?
|
| Autoantigens | 2 | 2001 | 118 | 0.080 |
Why?
|
| Incidence | 4 | 2013 | 3133 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2016 | 828 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 1362 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 2 | 2015 | 118 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1720 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 989 | 0.070 |
Why?
|
| Spleen | 2 | 2006 | 281 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12287 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1399 | 0.070 |
Why?
|
| Depression | 1 | 2015 | 1232 | 0.070 |
Why?
|
| Calpain | 1 | 2007 | 40 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1427 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 547 | 0.070 |
Why?
|
| Hypertension | 1 | 2015 | 1332 | 0.070 |
Why?
|
| Immunity, Active | 1 | 2006 | 7 | 0.060 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 6 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 2007 | 84 | 0.060 |
Why?
|
| Life Tables | 1 | 2006 | 28 | 0.060 |
Why?
|
| Complement Pathway, Alternative | 1 | 2006 | 14 | 0.060 |
Why?
|
| Blood Cells | 1 | 2006 | 50 | 0.060 |
Why?
|
| Muramidase | 1 | 2006 | 94 | 0.060 |
Why?
|
| Granulocytes | 1 | 2006 | 65 | 0.060 |
Why?
|
| Pediatrics | 1 | 2015 | 1158 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 96 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1025 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 143 | 0.060 |
Why?
|
| Case-Control Studies | 4 | 2017 | 3313 | 0.060 |
Why?
|
| Cryptosporidium | 1 | 2004 | 31 | 0.060 |
Why?
|
| Acetamides | 2 | 2001 | 47 | 0.060 |
Why?
|
| Family Health | 2 | 2005 | 256 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2016 | 171 | 0.050 |
Why?
|
| Racemethionine | 1 | 2023 | 6 | 0.050 |
Why?
|
| Mice, Inbred NOD | 3 | 2016 | 299 | 0.050 |
Why?
|
| Neoplasms | 2 | 2013 | 2799 | 0.050 |
Why?
|
| Aged | 6 | 2013 | 19727 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 102 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 14 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2017 | 61 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 683 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2006 | 1495 | 0.050 |
Why?
|
| Europe | 2 | 2013 | 359 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 395 | 0.050 |
Why?
|
| Teicoplanin | 1 | 2001 | 4 | 0.050 |
Why?
|
| Coagulase | 1 | 2001 | 23 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 215 | 0.050 |
Why?
|
| Citrulline | 1 | 2023 | 111 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2001 | 79 | 0.050 |
Why?
|
| Mesonephroma | 1 | 2001 | 1 | 0.050 |
Why?
|
| Papilloma | 1 | 2001 | 26 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 15 | 0.050 |
Why?
|
| Methicillin Resistance | 1 | 2001 | 118 | 0.050 |
Why?
|
| Self Tolerance | 1 | 2001 | 5 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2001 | 101 | 0.040 |
Why?
|
| Arginine | 1 | 2023 | 335 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2021 | 181 | 0.040 |
Why?
|
| United Kingdom | 1 | 2001 | 190 | 0.040 |
Why?
|
| Aza Compounds | 1 | 2000 | 15 | 0.040 |
Why?
|
| Streptococcus | 1 | 2000 | 60 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 222 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 644 | 0.040 |
Why?
|
| Body Composition | 2 | 2013 | 521 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 630 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2000 | 93 | 0.040 |
Why?
|
| Quinolines | 1 | 2000 | 103 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2001 | 2430 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1118 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 1363 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 880 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1172 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 572 | 0.040 |
Why?
|
| Artificial Limbs | 1 | 1997 | 7 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 463 | 0.040 |
Why?
|
| Pineal Gland | 1 | 1997 | 20 | 0.040 |
Why?
|
| Pinealoma | 1 | 1997 | 22 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2001 | 761 | 0.040 |
Why?
|
| Germinoma | 1 | 1997 | 32 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2017 | 21 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 197 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2020 | 323 | 0.040 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1998 | 77 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1997 | 71 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1997 | 163 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 471 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 191 | 0.030 |
Why?
|
| Learning | 1 | 2020 | 361 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1997 | 79 | 0.030 |
Why?
|
| Comorbidity | 1 | 2022 | 1528 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 879 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 29 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1998 | 196 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 780 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 130 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 230 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1902 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 225 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2016 | 290 | 0.030 |
Why?
|
| Mice | 4 | 2017 | 17750 | 0.030 |
Why?
|
| Cell Line | 1 | 2000 | 2756 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 727 | 0.030 |
Why?
|
| Rural Health | 1 | 1995 | 50 | 0.030 |
Why?
|
| Urban Health | 1 | 1995 | 78 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1621 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 217 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 309 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3689 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1505 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 188 | 0.030 |
Why?
|
| Survival Rate | 1 | 1999 | 2050 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2015 | 139 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 561 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 1076 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2001 | 1538 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 739 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2056 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 561 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 1294 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2013 | 40 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 801 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2013 | 73 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2017 | 826 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 1995 | 138 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 471 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1692 | 0.020 |
Why?
|
| Length of Stay | 1 | 1997 | 1310 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 1039 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 473 | 0.020 |
Why?
|
| Linezolid | 2 | 2001 | 25 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 1244 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 2414 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1633 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1065 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 471 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2001 | 7 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 415 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 2061 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 2909 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 1315 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3431 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2017 | 2603 | 0.020 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2005 | 62 | 0.020 |
Why?
|
| Israel | 1 | 2005 | 46 | 0.020 |
Why?
|
| Arabs | 1 | 2005 | 29 | 0.020 |
Why?
|
| Jews | 1 | 2005 | 32 | 0.020 |
Why?
|
| Atlantic Ocean | 1 | 2004 | 2 | 0.010 |
Why?
|
| Oocysts | 1 | 2004 | 3 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2005 | 97 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 22 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2004 | 124 | 0.010 |
Why?
|
| Glutens | 1 | 2004 | 10 | 0.010 |
Why?
|
| Transglutaminases | 1 | 2004 | 24 | 0.010 |
Why?
|
| Species Specificity | 1 | 2004 | 551 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 430 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1017 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2005 | 281 | 0.010 |
Why?
|
| Denmark | 1 | 2001 | 34 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2001 | 2 | 0.010 |
Why?
|
| Proinsulin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 259 | 0.010 |
Why?
|
| Virginiamycin | 1 | 2000 | 3 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 9 | 0.010 |
Why?
|
| Erythromycin | 1 | 2000 | 20 | 0.010 |
Why?
|
| Oxazoles | 1 | 2000 | 23 | 0.010 |
Why?
|
| Epithelium | 1 | 2001 | 365 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 194 | 0.010 |
Why?
|
| Vagina | 1 | 2001 | 185 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2004 | 781 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2001 | 408 | 0.010 |
Why?
|
| Environment | 1 | 2000 | 142 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 378 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 798 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1554 | 0.010 |
Why?
|
| Triglycerides | 1 | 1998 | 576 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1818 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1534 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 3603 | 0.000 |
Why?
|